Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics ( (CLDI) ) just unveiled an announcement.
On October 27, 2025, Calidi Biotherapeutics entered into agreements with its former subsidiary, Nova Cell, Inc., to sell 22,500,000 shares of Nova Cell common stock, representing 75% of equity interest, for $6 million. This transaction, which includes a combination of debt cancellation and deferred consideration, results in Nova Cell no longer being a subsidiary of Calidi Biotherapeutics. The company anticipates annual savings of $0.5 million in general and administrative expenses following the sale. Additionally, the Material Purchase Agreement amends previous intellectual property arrangements, allowing Nova Cell to assume certain liabilities while Calidi retains stocks of specific cell lines for its use.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on the development and commercialization of innovative therapies. The company’s primary products and services involve advanced cell-based treatments, with a market focus on addressing unmet medical needs through cutting-edge biotechnology.
Average Trading Volume: 261,305
Technical Sentiment Signal: Sell
Current Market Cap: $7.74M
For detailed information about CLDI stock, go to TipRanks’ Stock Analysis page.